Both hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are characterized by thrombotic microangiopathy (TMA), affecting mainly the kidney and brain, respectively. Diagnosis ...

Hemolytic uremic syndrome is of two types - the classification is based on the history of prodromal diarrhea. The type seen in children is called typical HUS. It usually starts after a diarrheal ...

Banerjee R, Hersh AL, Newland J, et al; on behalf of the Emerging Infections Network Hemolytic-Uremic Syndrome Study Group Most (92%) of the cases were confirmed by culture with the remaining 8% being ...

Hemolytic uremic syndrome (HUS) is the major cause of acute renal failure in children. It follows gastroenteritis caused by a Shiga toxin-producing E. coli strain, most frequently O157:H7, though ...

The lesions of Stx-related hemolytic–uremic syndrome, which are indistinguishable from those of its atypical form on the basis of standard histologic analysis, are characterized by thickening of ...

The research population consisted of 65 aHUS patients, referred to the Paediatric Nephrology Centre of the Radboud University Medical Centre. The patients were of Dutch or Belgian origin with a ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Atypical hemolytic uremic syndrome is a ...

- At 26 weeks, 54% of adults and 71% of children treated with ULTOMIRIS demonstrated Complete Thrombotic Microangiopathy (TMA) Response - Atypical HUS affects both adults and children and many ...

A University of Calgary–led research team finds that only 7% of children infected with Shiga toxin–producing Escherichia coli (STEC) developed hemolytic uremic syndrome (HUS) during a 395-case ...

The hemolytic–uremic syndrome, which is characterized by nonimmune hemolytic anemia, thrombocytopenia, and renal impairment, occurs most frequently in young children. Most cases are secondary to ...

Please provide your email address to receive an email when new articles are posted on . Researchers reviewed the efficacy of ravulizumab based on 2-year data from two phase 3, single-arm studies. eGFR ...